Pursuant to regulation 30 of the Securities Exchange Borad of India (LODR) Regulations, 2015, please find enclosed herewith the press release on un-audited financial results for the quarter and half year ended 30th September, 2026

E; INDO BORAX & CHEMICALS LIMITED T/ CIN: L24100MH1980PLC023177 Regd. Office: 506, 5t Floor, Tulsiani Chambers, Free Press Journal Marg, Nariman Point, Mumbai-400021, Tel: 022-35218591, email: info@indoborax.com Corp. Office : 201-A, Vedanta, 779A, Makwana Road, Marol Village, Andheri (E), Mumbai:400 059 Date: 11t November, 2026 To, To, BSE Limited, National Stock Exchange of India Ltd, Corporate Relationship Department, Listing Department, Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Fort, Bandra-Kurla Complex, Mumbai - 400 001 Bandra (East), Mumbai- 400 051 Stock Code: 524342 Stock Code: INDOBORAX Dear Sir / Madam, Subject: Press Release on Un-Audited (Standalone and Consolidated) Financial Results for the quarter and half year ended September 30, 2026 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release on the Un-Audited (Standalone and Consolidated) Financial Results for the quarter and half year ended September 30, 2026. We request you to kindly take the same on record. Thanking you. For Indo Borax & Chemicals Limited Pravin Chavan Company Secretary & Compliance Officer Membership No.: A16857 Encl: As above Elndo Borax & Chemicals Ltd. Indo Borax H1FY27 Consolidated Operating Income up 16.0% to Rs 129.29 crore; Adjusted EBITDA up 22.9% e Consolidated Adjusted EBITDA for H1FY27 stood at Rs. 28.09 crore, while the Adjusted EBITDA margin stood at 21.7% e Company completes its acquisition of 64.26% stake in Kronox Lab Sciences Ltd and appoints Mr. Suresh Kalra as Managing Director and Chief Executive Officer at Kronox e Received Board approval for amalgamation of its wholly owned subsidiary- Indoborax Infrastructure Private Ltd with Indo Borax Chemicals, subject to necessary regulatory approvals Mumbai, November 11, 2026: Indo Borax & Chemicals Ltd (BSE: 524342; NSE: INDOBORAX), one of India's leading manufacturers of boron-based chemicals, posted 16.0% growth in consolidated operating income for H1FY27 to Rs. 129.29 crore, up from Rs. 111.42 crore in H1FY26. The company’s consolidated Profit AftTaex fror H1FY27 stood at Rs. 21.00 crore, compared to Rs. 26.47 crore. The company’s Adjusted EBITDA and PAT margins (both on a consolidated basis) for H1IFY27 stood at 21.7% and 15.4%, respectively. Consolidated Financial Highlights (Rs. Crore) Particulars Q2Fv27 | Q2Fy2e | SO H1Fv27 | HiFv2e | STOWth (%) (%) Operating Income 58.04 | 57.85 19| 12020 11142 16 Total Income 63.35 | 6142 31| 13626 | 118.01 155 EBITDA 148 105 (85.9) | 2128 2271 (6.3) EBITDA Margin (%) 25 18.2 165 204 *Adjusted EBITDA 7903 1058 (25.0)| 28.09 22.85 29 Adjusted EBITDA Margin =5 s e 205 PAT 475 | 1626 (70.8) 21 26.47 (20.7) PAT Margin (%) 7.5 %5 154 24 EPS (Rs.) 147 5.07 (71.0) 6.54 8.25 (20.7) * Adjusted EBITDA = EBITDA (+) ESOP expense (+) Forex gain For Q2FY27, the company’s Consolidated Operating income stood at Rs 58.94 crore, compared to Rs 57.85 crore in Q2FY26. Consolidated EBITDA for Q2 FY27 stood at Rs 7.93 crore, while PAT stood at Rs 4.75 crore. EBITDA margin came under pressure due to high raw material costs in the quarter, driven by global supply chain challenges. The company’s PAT margin in Q2 FY27 was net of expenses of Rs 6.64 crore, related to the acquisition of Kronox Lab Sciences Ltd as a subsidiary. Ell\do Borax & Chemicals Ltd. Commenting on the company’s performance during the quarter, Mr. Suresh Kalra, Managing Director & CEO, Indo Borax& Chemicals Ltd., said, “The quarter under review witnessed steady demand across our key product segments, despite the seasonal impact of the monsoon. However, profitability remained under pressure due to higher raw material costs and geopolitical uncertainties in the Middle East, thereby impacting the overall cost environment. We will continue to focus on operational efficiencies, prudent costmanagement and optimising product mix to navigate these challenges in the coming quarters. “The quarter under review also witnessed strategic integration and stabilisation of synergies with the recently acquired Kronox Lab Sciences, in terms of markets of distribution and procurement ecosystem. Going forward, we are confident of sustaining the growth momentum and strengthening our margins further, backed by diversification, premiumisation and disciplined execution”, further added Mr. Kalra. The company has also recently received Board approval to amalgamate its wholly owned subsidiary, Indoborax Infrastructure Private Ltd, with Indo Borax Chemicals. This will be subject to necessary approvals from NCLT and other regulatory authorities. “We expectthe proposed amalgamation to unlock greater operational efficiencies by enablingthe pooling and optimal utilisation of resources across the combined entity. It will also facilitate sharper management focus, simplify governance structures and enable more agile decision-making, thereby creating a more integrated and efficient organisation,” Mr. Kalra said. About Indo Borax & Chemicals Ltd. Indo Borax & Chemicals Ltd., established in 1980, is India’s leading manufactureorf boron-based chemicals and the industry benchmark for Boric Acid. Being the only company to hold a Food and Drug Administration (FDA) license for manufacturing Phama Grade Boric Acid as per the Indian Pharmacopoeia, Indo Borax operates the most modem Boric Acid, Disodium Octaborate Tetrahydrate (D.0.T.), and Borax plant in Pithampur, Madhya Pradesh. It was also the first company in India to receive a BIS license for manufacturing Technical Grade Boric Acid. Backed by over 28,000 shareholders, Indo Borax was featured in Forbes Asia Pacific’s Top 200 Under A Billion Dollar Public Companies (2023) and recognised by The Economic Times for its value-driven growth approach. [For Media Queries Deepali Shah 9029557708 deepali@fortunapr.com [For IR Queries Rajshree Ganguly 98338 07235 rajshree@fortunapr.com